Tivozanib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tivozanib: From Renal Cell Carcinoma to Endocervical Carcinoma
One-Sentence Summary
Tivozanib is a highly selective VEGFR-1/2/3 tyrosine kinase inhibitor, established as an anti-angiogenic therapy for renal cell carcinoma. The TxGNN model predicts it may be effective for Endocervical Carcinoma, but this prediction is currently supported by no registered clinical trials and no published literature — it rests entirely on a class-effect mechanistic hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Renal cell carcinoma (based on general pharmacological knowledge; not recorded in the current evidence pack) |
| Predicted New Indication | Endocervical Carcinoma |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack (original_moa: [Data Gap]). Based on the mechanistic annotation attached to the top prediction, tivozanib is a highly selective VEGFR-1/2/3 tyrosine kinase inhibitor with anti-angiogenic activity, a mechanism class well established in oncology.
Cervical (endocervical) carcinoma is a tumour type with known dependence on tumour angiogenesis, and anti-angiogenic agents such as bevacizumab already have demonstrated clinical benefit in cervical cancer. This creates a plausible class-effect rationale: if VEGF-pathway inhibition benefits cervical cancer as a class, a potent VEGFR TKI like tivozanib could theoretically extend to this setting.
However, this rationale is explicitly described in the evidence pack itself as a class-level hypothesis rather than drug-specific evidence — “tivozanib itself has no direct evidence in this indication.” The same TxGNN run also surfaced nine additional, extremely rare cervical/uterine adenocarcinoma subtypes (ranks 2–10, scores 99.76–99.80%) using similarly indirect class-analogy reasoning (e.g., comparison to ovarian serous carcinoma or endometrial carcinoma response to other anti-angiogenic TKIs). None of these tumour types have any tivozanib-specific clinical or literature data.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
No marketing authorizations are recorded in the current evidence pack. Tivozanib is listed as not marketed in the EU dataset used to generate this report, with zero authorizations on file.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (VEGFR-1/2/3 tyrosine kinase inhibitor, anti-angiogenic) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported only by a TxGNN computational score (L5, no clinical trials, no literature) and a class-effect mechanistic hypothesis that is explicitly not drug-specific. Combined with the missing safety data (marked as a Blocking data gap for TFDA-equivalent warnings/contraindications) and the drug’s “not marketed” EU status, there is currently no basis to advance this indication beyond hypothesis stage.
To proceed, the following is needed:
- Official SmPC/labeling data (warnings, contraindications, DDI) to clear the Blocking safety data gap
- Confirmed mechanism of action documentation from DrugBank or equivalent source
- At minimum, preclinical or case-level evidence directly linking tivozanib to cervical/endocervical carcinoma before considering trial design
- Clarification of tivozanib’s actual EU regulatory status, since “not marketed” in this dataset should be cross-checked against known authorizations (e.g., Fotivda)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.